Completed NA INTERVENTIONAL 2-arm NCT04675255

Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY)

WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINE

Sponsor: Janssen Scientific Affairs, LLC

Conditions Adiposity HIV I Infection

Interventions Frequently sampled glucose tolerance testing MRI scan to assess intrahepatic triglyceride content abdominal subcutaneous adipose tissue biopsy

Updated 7 times since 2021 Last updated: Aug 1, 2023 Started: Jan 1, 2021 Primary completion: Jun 8, 2023 Completion: Jun 8, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Adiposity and HIV I Infection, this trial is completed. The trial is conducted by Janssen Scientific Affairs, LLC and has accumulated 7 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2023 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Jul 2022 — Sep 2023 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Mar 2021 — Jul 2022 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Mar 2021 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Scientific Affairs, LLC
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States